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Patient daily score for gastrointestinal symptoms on didanosine tablet wk or EC capsule wk and . All comparisons except week abdominal cramps are significant at P . for the difference compared with week means paired t-test statistic . Symptom severity was rated on a -point scale absent, minimal, mild, moderate, moderately severe, severe, and very severe . Abstract Pharmacological and clinical properties of didanosine VIDEX , a nucleoside reverse transcriptase inhibitor. Masahiko OKIYAMA, Hiroaki KAWASHIMA and Sachi FUKUNISHI Marketing , Bristol Pharmaceuticals K.K., -Nishi-Shinjuku -chome, Shinjuku-ku, Tokyo -, Japan . Folia Pharmacol. Jpn. Nippon Yakurigaku Zasshi 120, An active metabolite, ddATP, of didanosine that is an analogue of purine-nucleoside a component of nucleic acid was known to inhibit the activity of DNA polymerase for E. coli. In , Dr. Michiya et al. of NCI reported that didanosine and ddA inhibited replication of the human immunodeficiency virus HIV . This discovery led to the clinical application of both the compounds. Didanosine, after being uptaken into a cell, becomes an active metabolite, ddATP, to inhibit a reverse transcriptase of HIV. Compared with zidovudine, didanosine has weak cytotoxicity both in vitro and in vivo. Didanosine, which is recommended as a first-line therapy drug in the Japanese Guideline on an anti-HIV Infection Therapy, was approved as twice-daily Videx Tablet and Dry Syrup formulations for launch in June . In March , a once-daily Videx EC Capsule formulation was approved and launched, having expected adherence improvements in HIV AIDS patients. Keywords: didanosine; VIDEX; NRTI; HIV-infection; EC Capsule
